The Impact of Genetic Mutational Typing of Endometrial Carcinoma for Adjuvant Oncologic Treatment and Treatment Outcome
Chapter from the book:
Bilgili,
A.
(ed.)
2023.
Current Researches in Health Sciences-III.
Synopsis
The adjuvant treatment of endometrial carcinomas took a different turn when ESGO/ESTRO/ESP announced its prognostic risk group guide in 2020. The Cancer Genome Atlas (TCGA) Research Network Classification and the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) algorithm were integrated into clinical practice. Therefore, by combining genomic traits with molecular subtypes, doctors have enhanced patient care and risk stratification for endometrial cancer. Surgery (hysterectomy and bilateral salphingooopherectomy with or without lymph node dissection) is the primary treatment for early-stage, low-grade, low-risk tumors. Vaginal brachytherapy in an adjuvant setting has secured the treatment success for local control. Intermediate-high-risk cancer patients are scheduled for adjuvant chemoradiation and/or vaginal brachytherapy.
Keywords:
How to cite this book
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Published
DOI
Categories
Copyright (c) 2023 Ali Bilgili; Fatih Baygutalp- Lale Duysak- Edip Urhan- H. Yeşim Can- Sevil Alkan- Ali Emre Sevik- Buse Keskindağ- Veysel Tosun- Bengü Depboylu- Ege Rıza Karagür- Fatimeh Alghazawi- Bilge Büyükşirin- Büşra Candiri- Amine Nur Arıkan- Sanem Can Çolak- Feride Mehmetoğlu- Ayşe Gülbin Kavak- Merve Gördağ- İ. İlknur Uysal- Aytül Bayraktar- Nastaran Azami- Amirkasra Dehghani- Elif Sibel Aslan- Sajjad Eslamkhah